SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Forsgren Mikael)
 

Sökning: WFRF:(Forsgren Mikael) > Saroglitazar improv...

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients

Siddiqui, Mohammad Shadab (författare)
VCU, VA USA
Parmar, Deven (författare)
Zydus Therapeut, NJ USA
Shaikh, Farheen (författare)
Zydus Therapeut, NJ USA
visa fler...
Forsgren, Mikael (författare)
Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Centrum för medicinsk bildvetenskap och visualisering, CMIV
Patel, Samarth (författare)
Leigh Valley Hlth Network, PA USA
Bui, Anh Tuan (författare)
VCU, VA USA
Boyett, Sherry (författare)
VCU, VA USA
Patel, Vaishali (författare)
VCU, VA USA
Sanyal, Arun J. (författare)
VCU, VA USA
visa färre...
 (creator_code:org_t)
LIPPINCOTT WILLIAMS & WILKINS, 2023
2023
Engelska.
Ingår i: Liver transplantation. - : LIPPINCOTT WILLIAMS & WILKINS. - 1527-6465 .- 1527-6473. ; 29:9, s. 979-986
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • NAFLD is common after liver transplantation (LT) and is associated with an increased metabolic burden. Currently, there is a paucity of investigations into the treatment of post-LT NAFLD. In the present study, we evaluated the safety and efficacy of saroglitazar, a novel dual peroxisome proliferator-associated receptor & alpha;/& gamma; agonist, on the treatment of post-LT NAFLD and metabolic burden. This is a phase 2A, single-center, open-label, single-arm study in which patients with post-LT NAFLD received saroglitazar magnesium 4 mg daily for 24 weeks. NAFLD was defined by a controlled attenuation parameter & GE;264 dB/m. The primary endpoint was the reduction in liver fat as measured by MRI proton density fat fraction (MRI-PDFF). Secondary MRI-based metabolic endpoints included visceral adipose tissue, abdominal subcutaneous adipose tissue volumes, muscle fat infiltration, and fat-free muscle volume. Saroglitazar treatment led to a reduction in MRI-PDFF from 10.3 & PLUSMN;10.5% at baseline to 8.1 & PLUSMN;7.6%. A relative 30% reduction from baseline MRI-PDFF value was noted in 47% of all patients and 63% of patients with baseline MRI-PDFF >5%. Reduction in serum alkaline phosphatase was an independent predictor of MRI-PDFF response. Saroglitazar did not decrease fat-free muscle volume nor increase muscle fat infiltration, but did lead to a mild increase in visceral adipose tissue and abdominal subcutaneous adipose tissue. The study drug was well tolerated and a mild nonsignificant increase in serum creatinine was noted. Saroglitazar did not affect the weight. The study provides preliminary data demonstrating the safety and metabolic benefits of saroglitazar in LT recipients and underscores the importance of future studies to establish its efficacy after LT.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy